drugset
drugset / Trial / NCT04948554

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

NCT04948554 ↗

Phase 1 Terminated 5 enrolled Acceleron Pharma, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.

Timeline

Start
2023-03-10
Primary completion
2023-10-18
Completion
2023-10-18

Outcome

Outcome not reported

Stopped (Business): “Business Reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-2225 Unknown 0.25 mg/kg Subcutaneous
Subject MK-2225 Unknown 0.5 mg/kg Subcutaneous
Subject MK-2225 Unknown 1 mg/kg Subcutaneous
Subject MK-2225 Unknown 2 mg/kg Subcutaneous
Subject MK-2225 Unknown 2.25 mg/kg Subcutaneous
Subject MK-2225 Unknown 4.5 mg/kg Subcutaneous

Indications

systemic sclerosis